TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 50-56

  Kandioler Eckersberger, Daniela ^a   Ludwig, Carmen ^a   Rudas, Margarethe ^a   Kappel, Sonja ^a   Janschek, Elisabeth ^a   Wenzel, Catharina ^a   Schlagbauer Wadl, Hermine ^a   Mittlböck, Martina ^a   Gnant, Michael ^a   Steger, Günter ^a   Jakesz, Raimund ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CYTOTOXICITY; DRUG MECHANISM; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CODON; CYCLOPHOSPHAMIDE; EPIRUBICIN; EXONS; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; INTRONS; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033971806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bergh, J. Time for integration of predictive factors for selection of breast cancer patients who need postoperative therapy? J. Natl. Cancer Inst., 89: 605-607, 1997.
2. Ellis, P., Smith, I., Ashley, S., Walsh, G., Ebbs, S., Baum, M., Sacs, N., and McKinna, J. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol., 16: 107-114, 1998.
3. Harris, C. C. Structure and function of the p53 tumor suppresser gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
4. Fisher, D. E. Apoptosis in cancer therapy. Crossing the threshold. Cell, 78: 539-542, 1994.
5. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
6. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
7. Silvestrini, R., Veneroni, S., Benini, E., Daidone, M. G., Luisi, A., Leutner, M., Maucione, A., Kenda, R., Zucali, R., and Veronesi, U. Expression of p53, gluthathione, S-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J. Natl. Cancer Inst., 89: 639-645, 1997.
8. Niskanen, E., Blomqvist, C., Franssila, K., Hietanen, P., and Wasenius, V. M. Predictive value of c-erbB-2, p53, cathepsin-D, and histology of the primary tumor in metastatic breast cancer. Br. J. Oncol., 76: 917-922, 1997.
9. Degeorges, A., De Roquancourt, A., Extra, J. M., Espie, M., Bourstyn, E., De Cremoux, P., Soussi, T., and Marty, M. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res. Treat., 47: 47-55, 1998.
10. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., Robert, N., Tormey D. C., and Allred, D. C. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J. Natl. Cancer Inst., 87: 1254-1256, 1995.
11. Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Sheperd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., Arnold, A., Vandenberg, T., MacKenzie, R., Robert, J., Ottaway, J., Burnell, M., Williams, C. K., and Tu, D., for the National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil, in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16: 2651-2658, 1998.
12. Bellamy, C. O. C. p53 and apoptosis. Br. Med. Bull., 53: 522-538, 1996.
13. Hortobagyi, G. N., Holmes, F. A., Ibrahim, N., Champlin, R., and Buzdar, A. U. The University of Texas M. D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin. Oncol., 24: S30-S33, 1997.
14. Multani, A. S., Li, C., Ozen, M., Yadav, M., Yu, D. F., Wallace, S., and Pathak, S. Paclitaxel and water-soluble poly(L-glutamic acid)-paclitaxel induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Cancer Res., 17: 4269-4274, 1997.
15. Lehmann, T. A., Bennett, W. P., Metcalf, R. A., Welsh, J. A., Ecker, J., Modali, R. V. p53 mutations, ras mutation, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 51: 4090-4096, 1991.
16. Kandioler-Eckersberger, D., Kappel, S., Mittlböck, M., Dekan, G., Ludwig, C., Janschek, E., Pirker, R., Wolner, E., and Eckersberger, F. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 117: 744-750, 1999.
17. Rush, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., Kris, M., and Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to Cisplatinum-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res., 55: 5038-5042, 1995.
18. Stal, O., Stenmark-Askmalm, M., Wingren, S., Rutquist, L. E., Lambert, S., Ferraud, L., Sullivan, S., Carstensen, J., and Nordenskjöld, B. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol., 34: 767-770, 1995.
19. Pollack, I. F., Hamilton, R. L., Finkelstein, D. S., Campbell, J. W., Martinez, A. J., Sherwin, R. N., Bozik, M. E., and Gollin, S. M. The Relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res., 57: 304-309, 1997.
20. Milner, J. DNA damage, p53 and anticancer therapies. Nat. Med., 1: 879-880, 1995.
21. Lanni, J. S., Lowe, S. W., Licitra, E. J., Liu, J. O., and Jacks, T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 94: 9679-9683, 1997.
22. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
23. Wu, S. G., and El-Deiry, W. S. p53 and chemosensitivity. Nat. Med., 2: 255-256, 1996.
24. 1 arrest. Cancer Res., 58: 396-401, 1998.
25. Delia, D., Mizutani, S., Lamorte, G., Goi, K., Iwata, S., and Pierotti, M. A. p53 activity and chemotherapy. Nat. Med., 2: 724-725, 1996.
26. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
27. Di Leonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G., and Wahl, G. M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res., 57: 1013-1019, 1997.
28. Derry, W. B., Wilson, L., and Jordan, M. A. Low potency of Taxol at microtubule minus ends: implications for ist antimitotic and therapeutic mechanism. Cancer Res., 58: 1177-1184, 1998.
29. Gan, Y., Wientjes, M. G., Lu, J., and Au, J. L. S. Cytostatic and apototic effects of paclitaxel in human breast tumors. Cancer Chemother. Pharmacol., 42: 177-182, 1998.
30. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
31. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
32. Molina, R., Segui, M. A., Climent, M. A., Bellmunt, J., Albanell, J., Fernandez, M., Filella, X., Jo, J., Gimenez, N., Iglesias, E., Miralles, M., Alonso, C., Peiro, G., Perez-Picanol, E., and Ballesta, A. M. p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res., 18: 507-512, 1998.
33. Tolbert, D. M., Noffsinger, A. E., Miller, M. A., DeVoe, G. W., Stemmermann, G. N., Macdondald, J. S., and Fenoglio-Preiser, C. M. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod. Pathol., 12: 54-60, 1999.
34. Henson, D. E. Loss of p53 immunostaining intensity in breast cancer. J. Natl. Cancer Inst., 88: 1015-1019, 1996.
35. Sjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
36. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
37. Moskovic, E. C., Mansi, J. L., King, D. M., Murch, C. R., and Smith, I. E. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin. Radiol., 47: 339-344, 1993.